OBJECTIVE: We planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose. METHODS: Five consecutive weekly administrations of docetaxel were accompanied by radiotherapy for patients diagnosed with squamous cell carcinoma of the head and neck. The starting dose of docetaxel was 10 mg/m(2) with escalation at 2 mg/m(2) per step. RESULTS: Fifteen patients were enrolled in this trial. The maximal tolerated dose was 14 mg/m(2), so the recommended dose was determined as 12 mg/m(2). Hematological toxicity was sufficiently weak. Common dose-limiting toxicity was stomatitis within the radiation field. CONCLUSIONS: This protocol was thought to be practical for elderly patients or those with medical complications.
OBJECTIVE: We planned a phase I study of radiotherapy combined with weekly docetaxel for elderly patients or patients with complications to find out the optimal dose. METHODS: Five consecutive weekly administrations of docetaxel were accompanied by radiotherapy for patients diagnosed with squamous cell carcinoma of the head and neck. The starting dose of docetaxel was 10 mg/m(2) with escalation at 2 mg/m(2) per step. RESULTS: Fifteen patients were enrolled in this trial. The maximal tolerated dose was 14 mg/m(2), so the recommended dose was determined as 12 mg/m(2). Hematological toxicity was sufficiently weak. Common dose-limiting toxicity was stomatitis within the radiation field. CONCLUSIONS: This protocol was thought to be practical for elderly patients or those with medical complications.
Authors: M Di Genesio Pagliuca; C Perotti; G Apicella; A Galla; M Guffi; M Paolini; L Donis; V Amisano; S Torrente; I Manfredda; M Krengli Journal: Clin Transl Oncol Date: 2015-09-14 Impact factor: 3.405
Authors: N P Nguyen; J Vock; A Chi; V Vinh-Hung; S Dutta; L Ewell; S Jang; M Betz; F Almeida; M Miller; R Davis; T Sroka; R P Vo; U Karlsson; P Vos Journal: Strahlenther Onkol Date: 2012-06-03 Impact factor: 3.621